1
ME3738 is a new compound that attenuates liver disease in several models of acute and chronic liver inflammation.
2
Background: Hepatitis C infection induces an acute and chronic liver inflammation that may lead to cirrhosis, liver failure, or hepatocarcinoma.
1
One patient with recurrent hepatitis B developed chronic severe hepatitis B despite treatment.
2
The severity of recurrent hepatitis C virus (HCV) is likely related to several factors.
3
Methods: Twenty-nine cases of recurrent hepatitis C and 26 cases of ACR were included in this study.
4
One patient died of recurrent hepatitis C and graft failure without evidence of tuberculous infection at death.
5
Conclusions: Improving the outcome of recurrent hepatitis C may be achieved by reducing overall immunosuppression and avoiding abrupt variations in immunosuppression.
1
Gilead said chronic hepatitis B affects more than 400 million people worldwide.
2
Methods: One hundred forty-two unselected patients with chronic hepatitis C were included.
3
Conclusions: Entecavir therapy showed excellent efficacy in nucleoside-naive chronic hepatitis B patients.
4
Background and aim: Entecavir has demonstrated clinical efficacy for chronic hepatitis B.
5
This review focuses on the current treatment concepts for chronic hepatitis B.
6
Hepatic form is manifested by acute or chronic hepatitis, steatosis or cirrhosis.
7
Crescentic glomerulonephritis was diagnosed in two chronic hepatitis B surface antigen carriers.
8
All biopsies showed chronic hepatitis, of which 2 were associated with cirrhosis.
9
Methods: One hundred and twelve patients with biopsy-proven chronic hepatitis C were enrolled.
10
Aim: Predict the elimination of chronic hepatitis C in Catalan prisons.
11
The course of chronic hepatitis C is variable, but usually fibrosis advances slowly.
12
Comprehensive management of chronic hepatitis C takes into account cofactors of disease progression.
13
Twelve patients with chronic hepatitis C were included in the study.
14
Despite the declining incidence of acute HCV infection, chronic hepatitis C is common.
15
Current therapy for HCV-related chronic hepatitis is based on the use of interferon.
16
A hallmark of chronic hepatitis B is a dysfunctional HBV-specific T cell response.
